Sino Biological,Inc. provides recombinant protein and antibody reagents for life science researchers worldwide. It offers recombinant proteins, antibodies, cDNA clones, kits, serum-free media, protein modification, qPCR primers, cell lysates, and purification reagents. The company also provides comprehensive solutions, including autoimmune disease research, kinase drug discovery, cytokine and growth factor, SARS-CoV-2 variants research, comprehensive CAR-T therapy, 3D organoids research, ADC development, influenza vaccine development, and multispecific antibody development solutions, as well as solutions for MSCs therapy and in vitro efficacy evaluation. It serves academic research institutions, biotech companies, and pharmaceutical companies. Sino Biological,Inc. was founded in 2016 and is headquartered in Beijing, China.
Metrics to compare | 301047 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship301047PeersSector | |
---|---|---|---|---|
P/E Ratio | 88.3x | 33.8x | −0.5x | |
PEG Ratio | −1.64 | −1.16 | 0.00 | |
Price/Book | 1.5x | 2.5x | 2.6x | |
Price / LTM Sales | 14.4x | 7.2x | 3.3x | |
Upside (Analyst Target) | 2.5% | 0.8% | 43.4% | |
Fair Value Upside | Unlock | 10.5% | 7.1% | Unlock |